Milliman Study on the Utility of ICER Reports for Private Payer Drug Coverage Decision-Making

PhRMA September 18, 2018

To download the full report, click here.

A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be very useful for private payers’ medicine coverage decisions. The whitepaper identifies several problems in applying ICER’s reports to inform coverage decisions by private payers. 

Download Full Report Download the One-pager